Is Mirati Therapeutics a Good Stock to Buy Now?
This stock could soar at the end of the month, but is it worth the risk?
Mirati Therapeutics
MRTX
MRTX
$77.02
$1.07
1.4%
BATS BZX Real Time Price as of October 22, 2019, 4:00 p.m. EDT
View Interactive MRTX Charts
Mirati Therapeutics, Inc.
News & Analysis: Mirati Therapeutics
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
Winners and Losers of Europe’s Big Cancer Meeting
Unfortunately, there were more of the latter.
4 Biotech Stocks With Big Catalysts in September
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
3 Top Biotech Stocks to Buy Right Now
These three biotech stocks should be outstanding long-term growth vehicles.
Read This Before You Buy Any New Cancer Drug Stocks
Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.
Here's Why Mirati Therapeutics Is Jumping Today
It looks like a target considered undruggable is actually within reach.
Here's Why Mirati Therapeutics Is Surging Today
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
Here's Why Mirati Therapeutics Jumped 55.8% in January
Investors cheered the biotech's plans to move its lead candidate forward.
Why Mirati Therapeutics Inc. Is Plunging Today
Shares tumbled after the company reported clinical data from an important phase 2 trial. Here's what investors need to know.
